Uneek Mehra

CIK: 0001881504

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BBOT

BridgeBio Oncology Therapeutics, Inc.

Officer

FDMT

4D Molecular Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

BBOT
BridgeBio Oncology Therapeutics, Inc.
Apr 1, 2026
Tax Payment(F)
Direct
524 shares at avg. $9.03$5K
BBOT
BridgeBio Oncology Therapeutics, Inc.
Mar 10, 2026
Award(A)
Direct
23.3K shares-
BBOT
BridgeBio Oncology Therapeutics, Inc.
Aug 26, 2025
Award(A)
Stock Option (Right to Buy)
Direct
633.6K shares-
FDMT
4D Molecular Therapeutics, Inc.
Mar 6, 2025
Award(A)
Stock Option (Right to Buy)
Direct
130K shares-

		Type	Shares	Price		Ownership
Apr 1, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Tax Payment(F)	524	$9.03	$4,732	Direct
Mar 10, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A)	23,330	-	$0	Direct
Aug 26, 2025	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	633,570	-	-	Direct
Mar 6, 2025	FDMT 4D Molecular Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	130,000	-	-	Direct

1-4 of 4 transactions

About Mehra Uneek

Mehra Uneek (SEC CIK 0001881504) files insider reports with the SEC as Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT) and Officer of 4D Molecular Therapeutics, Inc. (FDMT).

Signal8 holds 5 ownership filings by Mehra Uneek (1 Form 3, 4 Form 4), filed between Mar 10, 2025 and May 5, 2026. Those filings report 4 transactions, from Mar 6, 2025 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mehra Uneek's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Mehra Uneek

Apr 1, 2026: Tax withholding of BBOT shares (Form 4, code F).
Mar 10, 2026: Grant or award of BBOT shares (Form 4, code A).
Aug 26, 2025: Grant or award of BBOT derivative securities (Form 4, code A).
Mar 6, 2025: Grant or award of FDMT derivative securities (Form 4, code A).

Other insiders filing for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Cobo Marc, Principal Accounting Officer
Elmelech Idan, COO & Principal Financial Ofcr
Beltran Pedro, President and CEO
Ben Yong, Chief Med & Dev Officer
Chen Bihua, Director
Tipirneni Praveen P., Director

How to read Form 4 transaction codes